Compare PPL & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PPL | WAT |
|---|---|---|
| Founded | 1920 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Laboratory Analytical Instruments |
| Sector | Utilities | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9B | 29.3B |
| IPO Year | 2007 | 1996 |
| Metric | PPL | WAT |
|---|---|---|
| Price | $37.18 | $302.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 17 |
| Target Price | $40.00 | ★ $386.38 |
| AVG Volume (30 Days) | ★ 7.6M | 999.3K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | ★ 32.50 | 0.47 |
| EPS | 1.59 | ★ 10.76 |
| Revenue | ★ $9,042,000,000.00 | $3,165,286,000.00 |
| Revenue This Year | $6.76 | $104.66 |
| Revenue Next Year | $6.09 | $10.53 |
| P/E Ratio | ★ $23.31 | $28.06 |
| Revenue Growth | 6.85 | ★ 6.99 |
| 52 Week Low | $32.50 | $275.05 |
| 52 Week High | $39.09 | $414.15 |
| Indicator | PPL | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 41.83 |
| Support Level | $35.17 | $281.62 |
| Resistance Level | $38.20 | $308.14 |
| Average True Range (ATR) | 0.73 | 8.63 |
| MACD | -0.22 | 2.99 |
| Stochastic Oscillator | 31.79 | 63.96 |
PPL is a holding company of regulated utilities in Pennsylvania, Kentucky, and Rhode Island. The Pennsylvania regulated delivery and transmission segment distributes electricity to customers in central and eastern Pennsylvania. In Kentucky, LG&E and KU are involved in regulated electricity generation, transmission, and distribution. LG&E also provides regulated natural gas distribution. Rhode Island Energy operates electric and gas utilities in the state.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.